our Premium Content: News alerts, weekly reports and conference planners

GENE:

NPM1 (Nucleophosmin 1)

News alerts, weekly reports and conference planners

NPM1 Mediates mRNA Sorting into Extracellular Vesicles via Specific RNA Motif Binding and Phase Separation. (PubMed, Adv Sci (Weinh))

Additionally, EVs derived from the serum of non-small cell lung cancer (NSCLC) patients exhibit elevated levels of NPM1 protein and EGFR mRNA, suggesting relevance for this transportation mechanism to NSCLC pathogenesis. This study, therefore, not only enhances the understanding of the molecular mechanism underlying mRNA sorting into EVs but also provides valuable insights for potential therapeutic strategies targeting NSCLC.

3 days ago

Journal

EGFR (Epidermal growth factor receptor) • NPM1 (Nucleophosmin 1)

Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial (JCCG AML-12). (PubMed, Br J Haematol)

LSPC-Cycle, FLT3-ITD and NUP98::KDM5A were considered independent prognostic factors in multivariate analysis. Findings indicate the prognostic relevance of cellular hierarchy and the importance of integrating hierarchy-specific molecular profiles for improved risk stratification and treatment formulation.

3 days ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • MECOM (MDS1 And EVI1 Complex Locus) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • NUP214 (Nucleoporin 214) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GATA1 (GATA Binding Protein 1) • GLIS2 (GLIS Family Zinc Finger 2) • KDM5A (Lysine Demethylase 5A) • MLLT3 (MLLT3 Super Elongation Complex Subunit)

FLT3-ITD mutation

Mesothelin Expression in Acute Leukemia: Correlations With Immunophenotype, Cytogenetics, and Mutational Status. (PubMed, Appl Immunohistochem Mol Morphol)

In AML, it correlated with CD33 expression and inv(16)/t(16;16). In conclusion, mesothelin is rare in ALL but enriched in specific AML subtypes and not prognostic for survival.

4 days ago

Journal • IO biomarker

NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • KMT2A (Lysine Methyltransferase 2A) • MSLN (Mesothelin) • CD38 (CD38 Molecule) • KDM6A (Lysine Demethylase 6A) • CD33 (CD33 Molecule) • GATA2 (GATA Binding Protein 2) • PHF6 (PHD Finger Protein 6) • ITGAX (Integrin Subunit Alpha X) • CBLC (Cbl Proto-Oncogene C)

NPM1 mutation • CBL mutation

ALK-positive ALCL: first described adult case of synchronous CNS and systemic involvement at presentation: a case report and review of the literature. (PubMed, Br J Neurosurg)

The patient was treated with a modified MARIETTA protocol (without rituximab) and consolidated with a carmustine-based autologous stem cell transplant. shows complete metabolic response on PET-CT and MRI brain. This case presents the first successful treatment of a synchronous presentation of CNS and systemic ALK-positive ALCL, and the importance of a multidisciplinary approach for diagnosis.

6 days ago

Journal

ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)

ALK positive • ALK fusion • ALK translocation

Rituxan (rituximab) • carmustine

Oncogenic Role and Clinical Significance of NPM1 in Colorectal Cancer via the AKT/mTOR Signaling Pathway. (PubMed, Anticancer Res)

NPM1 acts as an oncogenic driver in colorectal cancer by activating the AKT/mTOR signaling pathway. Elevated NPM1 expression highlights its potential as a diagnostic, prognostic, and therapeutic biomarker in CRC.

7 days ago

Journal

NPM1 (Nucleophosmin 1) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2) • JUN (Jun proto-oncogene)

Case Report: Pediatric AML with TBC1D15::RAB21 fusion and FLT3-ITD/NPM1 co-mutation: diagnostic pitfalls in morphologic mimicry of acute promyelocytic leukemia. (PubMed, Front Oncol)

The patient achieved sustained remission following risk-adapted AML chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT). This case underscores three critical points in pediatric AML: (1) the essential role of integrated molecular profiling in resolving morphologic ambiguities to prevent misclassification; (2) the complex prognostic impact of FLT3-ITD/NPM1 co-mutations in childhood AML; and (3) the potential therapeutic efficacy of allo-HSCT for rare fusion-driven subtypes.

8 days ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • MPO (Myeloperoxidase)

FLT3-ITD mutation • NPM1 mutation • CD33 positive

Identification and validation of HOXB3 hypomethylation as a novel prognostically epigenetic biomarker in acute myeloid leukemia. (PubMed, Front Immunol)

AML with HOXB3 hypomethylation usually has unique genetic patterns such as a normal karyotype, cytogenetic/molecular-intermediate risk, and mutations in FLT3-ITD, NPM1 and DNMT3A. Despite these associations, HOXB3 hypomethylation may serve as an independent prognostic biomarker for AML.

9 days ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • HOXA9 (Homeobox A9) • MIR193B (MicroRNA 193b) • HOXB3 (Homeobox B3)

FLT3-ITD mutation • FLT3 mutation • NPM1 mutation

Molecularly Imprinted Polymer Nanoparticles for Lung-Cancer-Cell-Surface Proteomics. (PubMed, Polymers (Basel))

Among these hub proteins, five proteins (NPM1, TOP2A, EZH2, PRKDC, and HNRNPK) were identified as clinically relevant when cross-referenced with the Human Protein Atlas database and the literature, highlighting their potential as diagnostic and therapeutic targets. These findings highlight the potential of nanoMIP-based snapshot imprinting as an alternative to 'classical' approaches for identifying potential protein targets for diagnostic and therapeutic applications.

9 days ago

Journal

NPM1 (Nucleophosmin 1) • TOP2A (DNA topoisomerase 2-alpha) • HNRNPK (Heterogeneous Nuclear Ribonucleoprotein K) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)

Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways. (PubMed, Cells)

In conclusion, our findings establish GAL3 and PDEδ, two KRAS-associated proteins, as promising combinatorial drug targets. Targeting these modulators provides an effective alternative strategy to overcome resistance mechanisms and enhance the clinical utility of existing KRAS inhibitors.

9 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • NPM1 (Nucleophosmin 1) • LGALS3 (Galectin 3) • IQGAP1 (IQ Motif Containing GTPase Activating Protein 1)

KRAS G12

Menin Inhibition in Acute Myeloid Leukemia: Pathobiology, Progress and Promise. (PubMed, Biomedicines)

We evaluate the latest data on various menin inhibitors-both as monotherapy and in combinations-emphasizing their efficacy and safety profiles. As new evidence continues to accumulate with recent drug approvals and ongoing randomized, phase 3 studies, menin inhibitors are rapidly becoming a component of the AML treatment paradigm for relapsed/refractory and likely newly diagnosed disease.

9 days ago

Review • Journal

NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • HOXA9 (Homeobox A9) • MEIS1 (Meis Homeobox 1)

NPM1 mutation • MLL rearrangement